The estimated Net Worth of David Aaron Lehman is at least $3.84 millió dollars as of 3 September 2024. Mr Lehman owns over 5,765 units of Pulmonx Corp stock worth over $1,575,947 and over the last 19 years he sold LUNG stock worth over $2,120,235. In addition, he makes $147,081 as Gen. Counsel & Sec. at Pulmonx Corp.
Mr has made over 22 trades of the Pulmonx Corp stock since 2012, according to the Form 4 filled with the SEC. Most recently he sold 5,765 units of LUNG stock worth $38,568 on 3 September 2024.
The largest trade he's ever made was exercising 36,000 units of Pulmonx Corp stock on 11 December 2017 worth over $648,000. On average, Mr trades about 2,364 units every 66 days since 2006. As of 3 September 2024 he still owns at least 203,348 units of Pulmonx Corp stock.
You can see the complete history of Mr Lehman stock trades at the bottom of the page.
David A. Lehman is the Gen. Counsel & Sec. at Pulmonx Corp.
As the Gen. Counsel & Sec. of Pulmonx Corp, the total compensation of Mr Lehman at Pulmonx Corp is $147,081. There are 2 executives at Pulmonx Corp getting paid more, with Glendon E. French having the highest compensation of $626,824.
Mr Lehman is 60, he's been the Gen. Counsel & Sec. of Pulmonx Corp since . There are no older and 5 younger executives at Pulmonx Corp.
David's mailing address filed with the SEC is C/O PULMONX CORPORATION, 700 CHESAPEAKE DRIVE, REDWOOD CITY, CA, 94063.
Over the last 4 years, insiders at Pulmonx Corp have traded over $195,808,760 worth of Pulmonx Corp stock and bought 107,681 units worth $1,883,657 . The most active insiders traders include Scientific Corp Boston, Thomas William Burns és Glendon E. Iii French. On average, Pulmonx Corp executives and independent directors trade stock every 13 days with the average trade being worth of $393,258. The most recent stock trade was executed by Geoffrey Beran Rose on 3 September 2024, trading 4,586 units of LUNG stock currently worth $30,726.
Pulmonx Corporation, a medical technology company, designs, develops, manufactures, and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Pulmonx Corp executives and other stock owners filed with the SEC include: